



(51) International Patent Classification:

C07D 213/38 (2006.01) *C07D 401/04* (2006.01)
C07D 213/48 (2006.01) *C07D 401/12* (2006.01)
A61K 31/44 (2006.01) *C07D 413/04* (2006.01)
A61P 35/00 (2006.01)

Mukund; 711-1325 Taylor Avenue, Winnipeg, Manitoba R3M 2K7 (CA). **SARASWAT, Neerja**; 1115-810 Allegheny Drive, Winnipeg, Manitoba R3T 5L2 (CA). **UL-LAH, Farman**; Apt# 311, 1325 Taylor Avenue, Winnipeg, Manitoba R3M 2K7 (CA).

(21) International Application Number:

PCT/EP2014/053674

(74) **Agent: BECK GREENER**; Fulwood House, 12 Fulwood Place, London London WC1V 6HR (GB).

(22) International Filing Date:

26 February 2014 (26.02.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2013 70113	27 February 2013 (27.02.2013)	DK
PA 2013 70114	27 February 2013 (27.02.2013)	DK
PA 2013 70115	27 February 2013 (27.02.2013)	DK
61/770,058	27 February 2013 (27.02.2013)	US
61/770,065	27 February 2013 (27.02.2013)	US
61/770,067	27 February 2013 (27.02.2013)	US
61/931,126	24 January 2014 (24.01.2014)	US

(71) **Applicant: EPITHERAPEUTICS APS** [DK/DK]; Ole Maaløes Vej 3, DK-2200 København N (DK).

(72) **Inventors: LABELLE, Marc**; 10 Melbourne Way, Basking Ridge, New Jersey 07920 (US). **BOESEN, Thomas**; Lipkesgade 25, 2.tv, DK-2100 København Ø (DK). **KHAN, Qasim**; 609-1305 Taylor Avenue, Winnipeg, Manitoba R3M 2K6 (CA). **VAKITI, Ramkrishna Reddy**; 1281 Grant Avenue #312, Winnipeg, Manitoba R3M 1Z6 (CA). **SHARMA, Utpal**; 24 Newdale Pl., Brampton, Ontario L6S 5Z2 (CA). **YANG, Ying**; 77 Riley Crescent, Winnipeg, Manitoba R3T 0J3 (CA). **MEHROTRA,**


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF HISTONE DEMETHYLASES



(I)

(57) **Abstract:** Compounds of the form In in which Q is selected from $-\text{CH}=\text{NR}^{12}$, $-\text{W}$, $-\text{CH}=\text{NHR}^{13}$, $-\text{CH}=\text{O}$ and $-\text{CH}(\text{OR}^{17})_2$ capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.